Pregnancy outcome among HIV positive and negative intravenous drug users

Anna Bucceri, Laura Luchini, Laura Rancilio, Emilio Grossi, Gabriele Ferraris, Gabriele Rossi, Mario Vignali, Fabio Parazzini

Research output: Contribution to journalArticle

Abstract

Objective: To analyze determinants of pregnancy outcome, among HIV infected and uninfected intravenous drug users. Study design: A total of 315 pregnant current intravenous drug users, IVDU (151 HIV infected and 164 HIV uninfected subjects) were referred to the Center for Pregnant Drug Addicts of the Mangiagalli Clinic, Milan Italy, for internatal care and delivery between 1985 and 1993. Results: HIV uninfected and infected mothers did not differ significantly according to type of pregnancy, gestational age at childbirth, mode of delivery, pregnancy outcome and newborn weight, height, head circumference, sex and Apgar at 1 and 5 min. Out of 133 children (born to HIV infected mothers) for whom HIV status was available, 20 (15%) were HIV infected or developed AIDS-related signs and symptoms during a 24 months follow-up. The distribution of HIV infected and non infected infants was not significantly different as regards maternal CD4 lymphocyte count, week of gestation at birth, mode of delivery, infant weight, height, head circumference and Apgar at 1 and 5 min. Conclusion: Our data show that HIV infected women in the early stages of HIV infection are not at a higher risk of adverse course of pregnancy than HIV uninfected women. Vertical transmission rates were not associated to newborn characteristics.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume72
Issue number2
DOIs
Publication statusPublished - Apr 1997

Keywords

  • CD4 lymphocyte count
  • HIV infection
  • Vertical transmission

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Fingerprint Dive into the research topics of 'Pregnancy outcome among HIV positive and negative intravenous drug users'. Together they form a unique fingerprint.

  • Cite this